Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21432120 | 1.00 | ALDH1A1 (0.43) | ALDH1A1HPGDCYP1A2NPC1CYP2D6 | |
| SCHEMBL21024550 | 0.87 | ADRB2 (0.39) | CYP1A2ADRB2ADRB1PGRTRPV3 | |
| SCHEMBL2632858 | 0.86 | TRPV4 (0.46) | ALDH1A1HPGDCYP1A2NPC1CYP2D6 | |
| SCHEMBL18552783 | 0.84 | ALDH1A1 (0.46) | ALDH1A1HPGDCYP1A2NPC1CYP2D6 | |
| SCHEMBL879123 | 0.82 | PGR (0.43) | ALDH1A1HPGDCYP1A2NPC1RAB9A | |
| SCHEMBL15157224 | 0.81 | ADRB2 (0.40) | CYP1A2ADRB2ADRB1PGRTRPV3 | |
| SCHEMBL16649358 | 0.81 | ADRB2 (0.40) | CYP1A2ADRB2ADRB1PGRTRPV3 | |
| SCHEMBL30892077 | 0.80 | CYP11B1 (0.45) | CYP1A2ADRB2ADRB1PGRTRPV3 | |
| SCHEMBL2824439 | 0.80 | CYP11B1 (0.45) | CYP1A2ADRB2ADRB1PGRTRPV3 | |
| SCHEMBL26085070 | 0.79 | ALDH1A1 (0.57) | ALDH1A1HPGDCYP1A2NPC1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11752149-B2 | Muscarinic acetylcholine M1 receptor antagonists | Pipeline Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20210161889-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2019-09-26 | — | — | US | disclosed |
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | CYP3A5, CYP3A43, CYP3A4 | ALDH1A1 850/4885HPGD 717/4885CYP1A2 79/4885 |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | ALDH1A1 1394/4885HPGD 2248/4885CYP1A2 871/4885 |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, MAVS | ALDH1A1 4534/4885HPGD 3404/4885CYP1A2 3720/4885 |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | ALDH1A1 4332/4885HPGD 270/4885CYP1A2 1075/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | ALDH1A1 3562/4885HPGD 1593/4885CYP1A2 4109/4885 |
| US-11752149-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | ALDH1A1 1394/4885HPGD 2248/4885CYP1A2 871/4885 |
| US-20210161889-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | ALDH1A1 1394/4885HPGD 2248/4885CYP1A2 871/4885 |
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | AHR, FURIN, CYP3A5 | ALDH1A1 375/4885HPGD 795/4885CYP1A2 75/4885 |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | ALDH1A1 4332/4885HPGD 270/4885CYP1A2 1075/4885 |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | CYP3A5, CYP3A43, CYP3A4 | ALDH1A1 850/4885HPGD 717/4885CYP1A2 79/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | ALDH1A1 3562/4885HPGD 1593/4885CYP1A2 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.